Transcutaneous immunization and immunostimulant strategies

被引:41
作者
Glenn, GM [1 ]
Kenney, RT [1 ]
Hammond, SA [1 ]
Ellingsworth, LR [1 ]
机构
[1] IOMAI Corp, Gaithersburg, MD 20878 USA
关键词
D O I
10.1016/S0889-8561(03)00094-8
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
The use of skin as a noninvasive route for vaccine delivery has great potential for safe use of potent immune system-stimulating compounds that can target the dense population of immune cells found in the skin. The use of such compounds to stimulate the skin immune system leads to highly potent immune responses, and this immune responsiveness, combined with an apparent high safety margin, has fostered a great deal of interest in targeting the skin with vaccines. The experience with the smallpox vaccine, the most successful vaccine in history and one that is delivered to the skin, suggests that the advances in delivery of vaccines to the skin will have an important impact on human health.
引用
收藏
页码:787 / +
页数:29
相关论文
共 65 条
[21]  
Glenn Gregory M, 2003, Expert Rev Vaccines, V2, P253, DOI 10.1586/14760584.2.2.253
[22]   Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant [J].
Glück, R ;
Mischler, R ;
Durrer, P ;
Fürer, E ;
Lang, AB ;
Herzog, C ;
Cryz, SJ .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) :1129-1132
[23]   Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract [J].
Gockel, CM ;
Bao, SS ;
Beagley, KW .
MOLECULAR IMMUNOLOGY, 2000, 37 (09) :537-544
[24]   Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against Respiratory Syncytial Virus (RSV) [J].
Godefroy, S ;
Goestch, L ;
Plotnicky-Gilquin, H ;
Nguyen, TN ;
Schmitt, D ;
Staquet, MJ ;
Corvaïa, N .
VACCINE, 2003, 21 (15) :1665-1671
[25]   Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells [J].
Guebre-Xabier, M ;
Hammond, SA ;
Epperson, DE ;
Yu, JM ;
Ellingsworth, L ;
Glenn, GM .
JOURNAL OF VIROLOGY, 2003, 77 (09) :5218-5225
[26]   Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously [J].
Güereña-Burgueño, F ;
Hall, ER ;
Taylor, DN ;
Cassels, FJ ;
Scott, DA ;
Wolf, MK ;
Roberts, ZJ ;
Nesterova, GV ;
Alving, CR ;
Glenn, GM .
INFECTION AND IMMUNITY, 2002, 70 (04) :1874-1880
[27]  
Hammond SA, 2001, CRIT REV THER DRUG, V18, P503
[28]   Transcutaneous immunization: T cell responses and boosting of existing immunity [J].
Hammond, SA ;
Walwender, D ;
Alving, CR ;
Glenn, GM .
VACCINE, 2001, 19 (17-19) :2701-2707
[29]   Transcutaneous immunization of domestic animals: opportunities and challenges [J].
Hammond, SA ;
Tsonis, C ;
Sellins, K ;
Rushlow, K ;
Scharton-Kersten, T ;
Colditz, I ;
Glenn, GM .
ADVANCED DRUG DELIVERY REVIEWS, 2000, 43 (01) :45-55
[30]   ELECTRON MICROSCOPIC EXAMINATION OF CORYNEBACTERIUM OVIS [J].
HARD, GC .
JOURNAL OF BACTERIOLOGY, 1969, 97 (03) :1480-+